BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Senhwa Biosciences Granted FDA IND for Phase II Study of Silmitasertib in Viral Community-Acquired Pneumonia (CAP)

The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether ...

November 22, 2023 | News

IASO Bio Sets Up Global CAR-T Center in China for Global MM Patients

On June 30, 2023, the China National Medical Products Administration (NMPA) approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCAS...

November 22, 2023 | News

Prospection AI Launches Single-source Patient-centric Platform in Australia to Boost Drug Commercialization

-Prospection—the pioneer of patient-centric intelligence—today announced the availability of Prospection AI, its self-service patient-cent...

November 21, 2023 | News

TB Alliance Initiates Phase 2 Trial for Next-Gen TB Drug in Five Countries

Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that will be tested as part of P...

November 17, 2023 | News

Groundbreaking milestone as the United Kingdom MHRA greenlights CASGEVY™, heralding a new era in CRISPR-based gene editing therapies

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) have shattered scientific barriers today as the United Kingdom Me...

November 17, 2023 | News

Eccogene and AstraZeneca Partner on ECC5004 for Cardiometabolic Diseases

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical,...

November 10, 2023 | News

Tempus Collaborates with Bristol Myers Squibb on Multimodal AI Research

"We are looking forward to expanding our relationship with Bristol Myers Squibb and furthering our shared commitment to advancing cancer research and treat...

November 09, 2023 | News

AdvanCell Doses First Patient in 212Pb-ADVC001 Clinical Trial for Metastatic Prostate Cancer in Australia

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...

November 09, 2023 | News

KN026 was Granted Breakthrough Therapy Designation by CDE

Gastric cancer is one of the most common gastrointestinal malignancies in the world, and the number of new cases and deaths of gastric cancer in China...

November 08, 2023 | News

Menarini Group and SciClone Pharma Partner to Bring ORSERDU® to China for Advanced Breast Cancer

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations,...

November 08, 2023 | News

CStone Partners with 3SBio for Nofazinlimab in China

CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in ma...

November 02, 2023 | News

First Patient Enrolled in Phase III Trial of Boan Biotech's Nivolumab

Nivolumab is a monoclonal antibody that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 (PD-1) receptor...

October 31, 2023 | News

Everest Medicines Receives Approval in Macau for Nefecon® in Primary IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercializ...

October 30, 2023 | News

Henlius Expands Partnership with Intas to Introduce Serplulimab in Europe and India

Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalt...

October 30, 2023 | News

Stay Connected